ICON Announces Senior Appointments in Scientific Operations, Medical Imaging and Real World Evidence

Dublin, Ireland, 12th October 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced senior appointments to its clinical research, medical imaging and commercialisation and outcomes services. Dr. Andrew Garrett has been appointed Executive Vice President, Scientific Operations, Dr. Paul McCracken has joined ICON as Vice President, Medical Imaging and Mr. Jim Carroll has been appointed Vice President, Real World Evidence (RWE).

Dr. Andrew Garrett has over 30 years’ experience within the pharmaceutical and CRO industries. As ICON’s EVP, Scientific Operations, Dr. Garrett has global responsibility for the strategic vision and operational execution of ICON’s scientific operations, including biostatistics and programming, pharmacovigilance, regulatory and medical affairs, medical writing, medical imaging and interactive technologies. Dr. Garrett joins ICON from Quintiles, where he led the global clinical analysis and reporting services group, and, prior to that, a number of biostatistics and data management roles. Dr. Garrett is a recognised thought leader in data-driven decision making and recently led a structural review of the methodology function of the UK’s Office for National Statistics to improve its ability to drive innovation and help equip it for the digital economy. Dr. Garrett holds a Bachelor of Science in Economics from the University of Leicester, a Masters in Science in Medical Statistics from the University of Newcastle and received a PhD in Statistics from The Open University in the UK.

Dr. Paul McCracken brings to ICON over 20 years’ experience in imaging and pharmaceuticals, with a strong track record of applying imaging and biomarkers to drug discovery and development across a range of therapeutic areas. Dr. McCracken joins ICON from Eisai, where he led the Imaging Centre of Excellence, which drives novel approaches for discovery targets and translational biomarkers, primarily through the introduction of imaging genetics and the acceleration of novel PET approaches. Prior to Eisai, Paul worked at Merck Research Laboratories, where he developed preclinical and translational imaging biomarkers and strategies to assess new molecular and biologic entities. Dr. McCracken holds a Bachelor of Science in Physics from The College of New Jersey, a Master of Science in Physics/Medical Physics from Wright State University and received his Ph.D. in Biomedical Engineering – Imaging from the Mayo Clinic College of Medicine.

Jim Carroll leads ICON’s RWE Center of Excellence, which develops real world data (RWD) and technology based solutions to support sponsors who are seeking to expand labelling and market access, while staying ahead of the growing demand for evidentiary requirements. Jim has over 20 years’ CRO and pharmaceutical experience and joins ICON from inVentiv Health, where he led the formation of a new business unit focused on providing novel RWD-driven services. Jim previously worked at IMS Health (now QuintilesIMS), where he led the development and commercialization of innovative RWD-based, global analytic solutions to improve decision outcomes across the biopharmaceutical product lifecycle. Jim holds a Bachelor of Science Degree in Organic Chemistry from the University of Massachusetts at Amherst and a Masters of Business Administration from the Questrom School of Business at Boston University.

Commenting on the appointments, Dr. Steve Cutler, ICON’s Chief Operating Officer, said: “I’m delighted to welcome Andrew, Paul and Jim to the ICON team. They bring a wealth of scientific operational, and commercialisation expertise to ICON which will help us to advance our clients’ products through their development pipelines and also drive their commercial success.”

About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,300 employees.
Further information is available at www.iconplc.com     

ICON Media Contact

Camille Frederix
Weber Shandwick
+44 (0) 207 067 0272

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.